ELVNYSE—64

Elevance Health, Inc.

Managed HealthcareVerified

Elevance Health, Inc. (ELV) is currently classified as Healthcare Services & Equipment within Managed Healthcare (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 125,827,000,000 USD, total equity 43,902,000,000, short-term debt 350,000,000, long-term debt 30,768,000,000. Net cash position is approximately -21,461,000,000 USD. Profitability profile: revenue 50,181,000,000, gross profit 0, operating income 2,086,000,000, net income 1,764,000,000. Return on equity ~4.0%. Return on assets ~1.4%. Operating-cash-flow to net-income ratio is 2.46. Risk profile from automated assessment: liquidity risk medium, dilution risk medium. Flags: Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk..

30-day price · ELV+104.28 (+35.7%)

Low$282.46High$399.64Close$396.01As of14 May, 00:00 UTC

Profile

CompanyElevance Health, Inc.

ExchangeNYSE

TickerELV

CIK0001156039

SICHospital & Medical Service Plans

SectorHealthcare

BusinessHealthcare Services & Equipment

Industry groupHealthcare Services & Equipment

IndustryManaged Healthcare

AI analysis

Business. Elevance Health, Inc. is classified under Healthcare / Managed Healthcare and appears profitable on the latest normalized snapshot.

Classification. Classification confidence is 0.92 based on verified market data; matched terms: Managed Healthcare, Healthcare Services & Equipment, Healthcare.

Key takeaways

Return on equity is about 4.0%.
Debt to equity is about 0.71x.

Financial snapshot

PeriodQ1 2026

CurrencyUSD

Revenue$50.18B

Gross profit—

Operating income$2.09B

Net income$1.76B

R&D—

SG&A—

D&A$354.0M

SBC$55.0M

Operating cash flow$4.33B

CapEx$235.0M

Free cash flow$4.10B

Total assets$125.83B

Total liabilities$81.78B

Total equity$43.90B

Cash & equivalents$9.66B

Long-term debt$30.77B

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY2025$199.12B$7.20B$5.66B$3.17B

FY2024$177.01B$7.86B$5.98B$4.55B

FY2025$177.01B$7.86B$5.98B$4.55B

FY2023$171.34B$8.50B$5.99B$6.76B

FY2024$171.34B$8.50B$5.99B$6.76B

PeriodGross %Op %Net %FCF %

FY2025————

FY2024————

FY2025————

FY2023————

FY2024————

PeriodAssetsEquityCashDebt

FY2025$121.49B$43.88B$9.49B—

FY2024$116.89B$41.31B$8.29B—

FY2025$116.89B$41.31B$8.29B—

FY2023$108.93B$39.31B$6.53B—

FY2024$108.93B$39.31B$6.53B—

PeriodOCFCapExFCFSBC

FY2025$4.29B$1.12B$3.17B$276.0M

FY2024$5.81B$1.26B$4.55B$191.0M

FY2025$5.81B$1.26B$4.55B$191.0M

FY2023$8.06B$1.30B$6.76B$289.0M

FY2024$8.06B$1.30B$6.76B$289.0M

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

Q1 2026$50.18B$2.09B$1.76B$4.10B

Q1 2026————

Q3 2025$149.38B$6.89B$5.12B$3.38B

Q2 2025$98.67B$5.59B$3.93B$2.61B

PeriodGross %Op %Net %FCF %

Q1 2026————

Q3 2025————

Q2 2025————

PeriodAssetsEquityCashDebt

Q1 2026$125.83B$43.90B$9.66B—

Q1 2026$121.49B$43.88B$9.49B—

Q3 2025$122.75B$43.95B$8.71B—

Q2 2025$121.94B$43.72B$8.56B—

PeriodOCFCapExFCFSBC

Q1 2026$4.33B$235.0M$4.10B$55.0M

Q1 2026————

Q3 2025$4.21B$823.0M$3.38B$246.0M

Q2 2025$3.07B$463.0M$2.61B$162.0M

Valuation

Market price—

Market cap—

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book$4.61B

Net cash-$21.46B

Current ratio1.5

Debt/Equity0.7

ROA1.4%

ROE4.0%

Cash conversion2.5%

CapEx/Revenue0.5%

SBC/Revenue0.1%

Asset intensity0.0

Dilution ratio1.4%

Risk assessment

Dilution riskMedium

Liquidity riskMedium

Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.

Industry benchmarks

Activity: Healthcare Services & Equipment · cohort 5 companies

MetricELVActivity

Op margin4.2%13.3% medp25 5.9% · p75 13.5%bottom quartile

Net margin3.5%8.6% medp25 2.7% · p75 12.7%below median

Gross margin—64.0% medp25 60.1% · p75 65.6%

R&D / revenue—6.9% medp25 6.7% · p75 7.1%

CapEx / revenue0.5%3.0% medp25 2.7% · p75 4.5%bottom quartile

Debt / equity71.0%69.3% medp25 63.4% · p75 74.5%above median

Observations

IR observations

Mean price target391.84 USD

Median price target388.00 USD

High price target491.45 USD

Low price target331.00 USD

Mean recommendation2.28 (1=strong buy, 5=strong sell)

Strong-buy count5.00

Buy count8.00

Hold count12.00

Sell count0.00

Strong-sell count0.00

Mean EPS estimate26.91 USD

Last actual EPS30.29 USD

Source: analysis-pipeline (hybrid)Generated: 2026-05-01 04:24 UTCJob: ef9c3421